Protein-based COVID-19 Authorized in Europe in 2024

Novavax, Inc. today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine for use in individuals aged 12 and older to prevent COVID-19 in the European Union.

As of October 9, 2024, Novavax's vaccine is in line with guidance from the U.S. Food and Drug Administration and the World Health Organization to target the SARS-CoV-2 virus JN.1 lineage during the fall of 2024.

In the U.S., Novavax is the only protein-based vaccine available in pharmacies such as CVS Pharmacy, Giant, Publix, and Rite Aid.